文献速递神经肿瘤

EGFR扩增与经典型亚型与复发性胶质母细胞瘤对贝伐珠单抗反应不佳相关

EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.
PubMed 文献 · J Neurooncol · 2019-01-24

该回顾性研究分析了2006至2014年在本院接受贝伐珠单抗治疗的复发性胶质母细胞瘤患者,按TCGA分子分型分层,发现经典型亚型及EGFR基因扩增与更短的无进展生存时间和贝伐珠单抗使用时间显著相关,作者认为这些发现可影响决策并需前瞻性验证。

要点

  • 经典型GBM患者贝伐珠单抗使用时间显著短于间质型、前神经型及神经型(2.7 vs 5.1 vs 6.4及6.0个月,p=0.011)。
  • 经典型亚型与EGFR基因扩增在单因素(p<0.001和p=0.007)及多因素分析(均p=0.010)中均与更短的无进展时间显著相关。
  • 作者认为这些发现可对决策产生重要影响,并应进一步前瞻性验证。

核心结论

  • 经典型亚型及EGFR基因扩增与复发性GBM患者接受贝伐珠单抗治疗后更短的无进展时间显著相关,作者认为这些发现可对决策产生重要影响并应进一步前瞻性验证。

研究设计与样本

  • 回顾性分析2006至2014年在本院接受贝伐珠单抗治疗的复发性胶质母细胞瘤患者,共80例有治疗前后影像及基因组亚型资料,EGFR基因扩增由FISH法检测。

主要发现

  • 经典型肿瘤患者贝伐珠单抗使用时间显著短于间质型、前神经型及神经型(2.7 vs 5.1 vs 6.4及6.0个月,p=0.011)。
  • 经典型亚型与EGFR基因扩增在单因素分析中均与更短的无进展时间显著相关(p<0.001和p=0.007)。
  • 经典型亚型与EGFR基因扩增在多因素分析中均与更短的无进展时间显著相关(均p=0.010)。

临床怎么用

  • 作者认为EGFR基因扩增和经典型亚型与复发性GBM患者接受贝伐珠单抗治疗后更短的无进展时间相关,这些发现可对决策产生重要影响。

局限性

  • 作者指出这些发现应进一步前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The highly vascular malignant brain tumor glioblastoma (GBM) appears to be an ideal target for anti-angiogenic therapy; however, clinical trials to date suggest the VEGF antibody bevacizumab affects only progression-free survival. Here we analyze a group of patients with GBM who received bevacizumab treatment at recurrence and are stratified according to tumor molecular and genomic profile (TCGA classification), with the goal of identifying molecular predictors of the response to bevacizumab. METHODS: We performed a retrospective review of patients with a diagnosis of glioblastoma who were treated with bevacizumab in the recurrent setting at our hospital, from 2006 to 2014. Treatment was discontinued by the treating neuro-oncologists, based on clinical and radiographic criteria. Pre- and post-treatment imaging and genomic subtype were available on 80 patients. We analyzed time on bevacizumab and time to progression. EGFR gene amplification was determined by FISH. RESULTS: Patients with classical tumors had a significantly shorter time on bevacizumab than mesenchymal, and proneural patients (2.7 vs. 5.1 vs. 6.4 and 6.0 months respectively, p = 0.011). Classical subtype and EGFR gene amplification were significantly associated with a shorter time to progression both in univariate (p < 0.001 and p = 0.007, respectively) and multivariate analysis (both p = 0.010). CONCLUSION: EGFR gene amplification and classical subtype by TCGA analysis are associated with significantly shorter time to progression for patients with recurrent GBM when treated with bevacizumab. These findings can have a significant impact on decision-making and should be further validated prospectively.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Hovinga KE, McCrea HJ, Brennan C, et al. EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma. J Neurooncol. 2019. PMID: 30680510. doi:10.1007/s11060-019-03102-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。